Cupid Q2 FY25 income up 29.7%; PAT up 96.2%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
Construction of the plant will commence in 2025 with first production expected to be in 2027
Growth markets revenue increased by 44 YoY to Rs. 812 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Subscribe To Our Newsletter & Stay Updated